Table 3.
Clinical Trials of Anti-Angiogenic Therapy Combined with Immunotherapy in the Treatment of NSCLC
| Trial | Phase | Disease | Anti-Angiogenic Agent(s) | ICI(s) | Chemotherapy | Status |
|---|---|---|---|---|---|---|
| NCT03377023 | I/II | Metastatic NSCLC | Nintedanib | Nivolumab/Ipilimumab | - | Recruiting |
| NCT04040361 | II | Stage IB/II/IIIA NSCLC | Ramucirumab | Pembrolizumab | - | Not yet recruiting |
| NCT03836066 | II | NSCLC | Bevacizumab | Atezolizumab | - | Recruiting |
| NCT03616691 | II | NSCLC | Bevacizumab | Atezolizumab | - | Not yet recruiting |
| NCT03896074 | II | NSCLC | Bevacizumab | Atezolizumab | - | Not yet recruiting |
| NCT03971474 | II | Stage IV or recurrent NSCLC | Ramucirumab | Pembrolizumab | Docetaxel/Gemcitabine (Hydrochloride)/Pemetrexed (Disodium) | Recruiting |
| NCT02681549 | II | Melanoma NSCLC |
Bevacizumab | Pembrolizumab | - | Recruiting |
| NCT03527108 | II | NSCLC | Ramucirumab | Nivolumab | - | Not yet recruiting |
| NCT03991403 | III | NSCLC | Bevacizumab | Atezolizumab | Pemetrexed/Carboplatin/Paclitaxel/Cisplatin | Not yet recruiting |
|
NCT01454102 (CheckMate 012) |
I | NSCLC | Bevacizumab | Nivolumab/Ipilimumab | Pemetrexed/Carboplatin/Paclitaxel/Cisplatin/Gemcitabine | Active, not recruiting* |
| NCT03689855 | II | NSCLC | Ramucirumab | Atezolizumab | - | Recruiting |
| NCT03713944 | II | Stage IV or recurrent NSCLC | Bevacizumab | Atezolizumab | Pemetrexed/Carboplatin | Recruiting |
|
NCT02366143 (Impower150) |
III | NSCLC | Bevacizumab | Atezolizumab | Pemetrexed/Carboplatin | Active, not recruiting* |
| NCT04147351 | II | Stage IIIB/IV NSCLC | Bevacizumab | Atezolizumab | - | Not yet recruiting |
| NCT04245085 | II | EGFR-mutant Stage IIIB/C or IV Nonsquamous NSCLC | Bevacizumab | Atezolizumab | Pemetrexed/Carboplatin/Paclitaxel | Not yet recruiting |
| NCT04194203 | III | NSCLC | Bevacizumab | Atezolizumab | Pemetrexed/Carboplatin/Paclitaxel | Not yet recruiting |
|
NCT02443324 (JVDF) |
I | Gastric Adenocarcinoma NSCLC Biliary Tract Cancer |
Ramucirumab | Pembrolizumab | - | Active, not recruiting* |
| NCT03786692 | II | Stage IV NSCLC | Bevacizumab | Atezolizumab | Pemetrexed/Carboplatin | Recruiting |
| NCT03647956 | II | EGFR-mutant Stage IIIB/IV NSCLC | Bevacizumab | Atezolizumab | Pemetrexed/Carboplatin | Recruiting |
| NCT02572687 | I | Gastric Cancer Gastroesophageal Junction Adenocarcinoma NSCLC Hepatocellular Carcinoma |
Ramucirumab | Durvalumab | - | Active, not recruiting |
| NCT02574078 | I/II | NSCLC | Bevacizumab | Nivolumab | Pemetrexed/Carboplatin/Paclitaxel/Cisplatin/Gemcitabine/Docetaxel | Active, not recruiting |
| NCT04151563 | I/II | NSCLC | Ramucirumab | Nivolumab/Ipilimumab | Docetaxel | Not yet recruiting |
| NCT04046614 | I/II | Lung adenocarcinoma | Nintedanib | Nivolumab | - | Recruiting |
| NCT03117049 | III | NSCLC | Bevacizumab | Nivolumab | Carboplatin/Paclitaxel | Active, not recruiting |
| NCT03307785 | I | Metastatic or stage IIIB NSCLC | Bevacizumab | Dostarlimab/TSR-022 | Pemetrexed/Carboplatin/Paclitaxel/Cisplatin | Active, not recruiting |
| NCT04211896 | II | NSCLC | Anlotinib | Nivolumab | - | Not yet recruiting |
| NCT04164745 | II | NSCLC | Anlotinib | Pembrolizumab | - | Recruiting |
| NCT04165330 | I/II | Soft tissue sarcoma NSCLC SCLC |
AL3818 (Anlotinib Hydrochloride) | Nivolumab | - | Recruiting |
| NCT04094909 | II | Stage IV NSCLC | Rh-endostatin | Pembrolizumab | - | Not yet recruiting |
| NCT03472560 | II | NSCLC Urothelial cancer |
Axitinib | Avelumab | - | Active, not recruiting |
| NCT04213170 | II | NSCLC with brain metastases | Bevacizumab | Sintilimab | - | Recruiting |
| NCT04124731 | II | NSCLC | Anlotinib | Sintilimab | Pemetrexed/Carboplatin/Cisplatin/Gemcitabine | Not yet recruiting |
| NCT04201990 | I/II | Lung cancer | Apatinib | Camrelizumab | - | Not yet recruiting |
| NCT04379739 | II | NSCLC | Apatinib | Camrelizumab | - | Not yet recruiting |
| NCT04203485 | III | PD-L1 positive NSCLC | Apatinib | Camrelizumab | Pemetrexed disodium/Paclitaxel/Carboplatin | Not yet recruiting |
| NCT04133337 | I/II | NSCLC | Apatinib | Camrelizumab | – | Not yet recruiting |
| NCT04239443 | II | Advanced NSCLC Uterine cancer Soft tissue sarcoma |
Apatinib | Camrelizumab | – | Recruiting |
| NCT04303130 | II | NSCLC | Endostar | Camrelizumab | – | Recruiting |
Abbreviations: NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; ICI, immune checkpoint inhibitor.